FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1714645007> ?p ?o ?g. }

• W1714645007 abstract "H ypertension is the most commonly encountered chronic medical condition in primary care practice and is a major risk factor for stroke and coronary artery disease. For decades, thiazide diuretics have been a recommended first line option for antihypertensive therapy. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommended thiazides as first line therapy unless a compelling indication existed for another agent. JNC-8 recommends diuretics as one of four acceptable first line options for non-black patients without chronic kidney disease (other options include angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, or calcium channel blockers), and as one of two acceptable options for African American patients without chronic kidney disease (the other option is calcium channel blockers). Hypokalemia frequently results from the administration of thiazide diuretics. This effect is more common with chlorthalidone than hydrochlorothiazide (HCTZ) or indapamide, and occurs in a dose dependent fashion. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), one of the largest trials of antihypertensive therapy (n=33,357), mean potassium levels at 4 years fell 0.2 mEq/L among chlorthalidone treated patients, and potassium fell below 3.5 mEq/L in 8.5% of patients at 4 years (as opposed to 1.9 % of amlodipine treated patients). Hypokalemia, when it occurs, usually appears within the first 2 weeks after initiating diuretic therapy. If hypokalemia occurs, clinicians have the option of beginning potassium chloride replacement therapy (typical doses are 20–40 mEq per day for patients with normal renal function), or beginning a potassium sparing diuretic. Potassium sparing diuretics include triamterene and amiloride (epithelial sodium channel inhibitors) and spironolactone and eplerenone (mineralocorticoid receptor antagonists). The choice of potassium replacement or a potassium-sparing diuretic has been typically left to the discretion of the clinician, as no evidence has suggested that the addition of potassium-sparing diuretics provides additional value in terms of blood pressure lowering or a reduction in cardiovascular events. From the patient perspective, a disadvantage of potassium replacement is the requirement to add either large pills that are often difficult to swallow, or a salty tasting solution to the thiazide. No studies exist of triamterene as monotherapy for the treatment of hypertension. In a recent Cochrane systematic review, authors evaluated the blood pressure lowering effect of potassium-sparing diuretics that block the epithelial sodium channel when given in combination with another antihypertensive agent. Only six trials of 496 patients existed; all six studies were performed in the 1980s. Two trials (n=211) evaluated the incremental benefit of triamterene 50mg per day when added to chlorthalidone at 25 to 50 mg per day. The addition of triamterene provided no incremental reduction in systolic blood pressure (−0.01, 95 % CI −3.63 to 3.61), or diastolic blood pressure (+0.20, 95 % CI −2.01 to 2.41), but total sample sizes were too small to draw any meaningful conclusions. In this issue of JGIM, Tu and colleagues queried a large network electronic medical record system to determine the incremental blood pressure lowering effect of triamterene. They identified 17,291 patients with a diagnosis of hypertension over an 8-year period and divided these patients into those with and without a pharmacy claim for triamterene. Patients who received triamterene were more likely to be female or African American, and less likely to have diabetes, coronary artery disease, congestive heart failure, a history of stroke, or chronic obstructive pulmonary disease. A direct comparison of the blood pressure values in these two groups would be confounded by substantial selection bias due to the nonrandom assignment between the groups. Tu et al. used a novel approach to attempt to correct for limitations inherent in these observational data. They used propensity score matching to estimate the probability that a patient would receive a particular treatment, based on logistic regression that adjusted for 14 clinical characteristics. They then stratified patients into quartiles of estimated propensity and compared the recorded blood pressures for those who had or had not received triamterene. They evaluated separately the impact of adding triamterene to HCTZ or to combinations of drugs that included HCTZ. They present no data on chlorthalidone use; in their network, triamterene was most commonly prescribed as a fixed combination pill with HCTZ (initial dose was HCTZ 25 mg daily and triamterene 37.5 mg daily). Published online September 18, 2015" @default.
• W1714645007 created "2016-06-24" @default.
• W1714645007 creator A5040102724 @default.
• W1714645007 date "2015-09-18" @default.
• W1714645007 modified "2023-09-22" @default.
• W1714645007 title "Triamterene in the Treatment of Hypertension: More Than Just Potassium Sparing?" @default.
• W1714645007 cites W180946569 @default.
• W1714645007 cites W1893697707 @default.
• W1714645007 cites W1916299283 @default.
• W1714645007 cites W2008895422 @default.
• W1714645007 cites W2025434152 @default.
• W1714645007 cites W2117140855 @default.
• W1714645007 cites W2126125759 @default.
• W1714645007 cites W2145144040 @default.
• W1714645007 cites W2475261460 @default.
• W1714645007 cites W2562329777 @default.
• W1714645007 cites W4211261740 @default.
• W1714645007 cites W979979263 @default.
• W1714645007 doi "https://doi.org/10.1007/s11606-015-3515-z" @default.
• W1714645007 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4700017" @default.
• W1714645007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26385116" @default.
• W1714645007 hasPublicationYear "2015" @default.
• W1714645007 type Work @default.
• W1714645007 sameAs 1714645007 @default.
• W1714645007 citedByCount "2" @default.
• W1714645007 countsByYear W17146450072017 @default.
• W1714645007 countsByYear W17146450072021 @default.
• W1714645007 crossrefType "journal-article" @default.
• W1714645007 hasAuthorship W1714645007A5040102724 @default.
• W1714645007 hasBestOaLocation W17146450071 @default.
• W1714645007 hasConcept C126322002 @default.
• W1714645007 hasConcept C126894567 @default.
• W1714645007 hasConcept C164705383 @default.
• W1714645007 hasConcept C2777622974 @default.
• W1714645007 hasConcept C2777748223 @default.
• W1714645007 hasConcept C2778242168 @default.
• W1714645007 hasConcept C2778653478 @default.
• W1714645007 hasConcept C2779646130 @default.
• W1714645007 hasConcept C2779918671 @default.
• W1714645007 hasConcept C2780361556 @default.
• W1714645007 hasConcept C2780427769 @default.
• W1714645007 hasConcept C2780437262 @default.
• W1714645007 hasConcept C71924100 @default.
• W1714645007 hasConcept C84393581 @default.
• W1714645007 hasConceptScore W1714645007C126322002 @default.
• W1714645007 hasConceptScore W1714645007C126894567 @default.
• W1714645007 hasConceptScore W1714645007C164705383 @default.
• W1714645007 hasConceptScore W1714645007C2777622974 @default.
• W1714645007 hasConceptScore W1714645007C2777748223 @default.
• W1714645007 hasConceptScore W1714645007C2778242168 @default.
• W1714645007 hasConceptScore W1714645007C2778653478 @default.
• W1714645007 hasConceptScore W1714645007C2779646130 @default.
• W1714645007 hasConceptScore W1714645007C2779918671 @default.
• W1714645007 hasConceptScore W1714645007C2780361556 @default.
• W1714645007 hasConceptScore W1714645007C2780427769 @default.
• W1714645007 hasConceptScore W1714645007C2780437262 @default.
• W1714645007 hasConceptScore W1714645007C71924100 @default.
• W1714645007 hasConceptScore W1714645007C84393581 @default.
• W1714645007 hasLocation W17146450071 @default.
• W1714645007 hasLocation W17146450072 @default.
• W1714645007 hasLocation W17146450073 @default.
• W1714645007 hasLocation W17146450074 @default.
• W1714645007 hasOpenAccess W1714645007 @default.
• W1714645007 hasPrimaryLocation W17146450071 @default.
• W1714645007 hasRelatedWork W1485849440 @default.
• W1714645007 hasRelatedWork W1924870810 @default.
• W1714645007 hasRelatedWork W1980897741 @default.
• W1714645007 hasRelatedWork W1990790675 @default.
• W1714645007 hasRelatedWork W2009868110 @default.
• W1714645007 hasRelatedWork W2019868326 @default.
• W1714645007 hasRelatedWork W2103278176 @default.
• W1714645007 hasRelatedWork W2104141891 @default.
• W1714645007 hasRelatedWork W2164264440 @default.
• W1714645007 hasRelatedWork W2166908706 @default.
• W1714645007 hasRelatedWork W2169028043 @default.
• W1714645007 hasRelatedWork W2172029844 @default.
• W1714645007 hasRelatedWork W2313782037 @default.
• W1714645007 hasRelatedWork W2342465070 @default.
• W1714645007 hasRelatedWork W2403941716 @default.
• W1714645007 hasRelatedWork W2416773334 @default.
• W1714645007 hasRelatedWork W2418084891 @default.
• W1714645007 hasRelatedWork W2528994698 @default.
• W1714645007 hasRelatedWork W76004658 @default.
• W1714645007 hasRelatedWork W84104048 @default.
• W1714645007 isParatext "false" @default.
• W1714645007 isRetracted "false" @default.
• W1714645007 magId "1714645007" @default.
• W1714645007 workType "article" @default.